Results 161 to 170 of about 81,988 (275)

Is a Clinical Trial With a Non‐Bioequivalent Batch Necessary? The Critical Role of Intrasubject Variability in Olaparib Formulation Bridging by PBPK

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 203-213, July 2026.
Although physiologically based pharmacokinetic (PBPK) modeling is increasingly being used to support oral drug formulation bridging, the acceptance by regulatory agencies is low. One of the primary concerns is the absence of clinical pharmacokinetic (PK) data from a non‐bioequivalent (non‐BE) batch during model validation.
Jin Dong, Andrea Moir, Xavier Pepin, Elizabeth Lowe, Sandy Hopkins, Weifeng Tang, Diansong Zhou   +6 more
wiley   +1 more source

[Corrigendum] Influence of MLH1 on colon cancer sensitivity to poly(ADP‑ribose) polymerase inhibitor combined with irinotecan. [PDF]

Int J Oncol
Tentori L, Leonetti C, Muzi A, Dorio AS, Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.   +10 more
europepmc   +1 more source

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

International Journal of Cancer, Volume 159, Issue 1, Page 257-268, 1 July 2026.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida, Kosuke Hiramatsu, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Tadashi Iwamiya, Shinya Matsuzaki, Tetsuji Naka, Yutaka Ueda, Tadashi Kimura, Michiko Kodama   +10 more
wiley   +1 more source

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). [PDF]

Cancer Innov
Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center.   +5 more
europepmc   +1 more source

Exosome Secretion Drives Chemo‐Resistance of Temozolomide in Glioblastoma

Journal of Extracellular Biology, Volume 5, Issue 7, July 2026.
ABSTRACT Temozolomide (TMZ) is a first‐line chemotherapeutic agent for the treatment of glioblastoma (GBM), while a majority of patients do not effectively respond to TMZ owing to the multiple resistance mechanisms. In this study, we found that TMZ treatment substantially increased the exosome secretion from GBM cell line.
Wenpei Li, Shaoping Jiang, Kun Liu, Zhi Li, Jun Yang, Weimin Liu, Yuanyu Huang, Minghui Yang, Shuai Guo, Shaobo Ruan   +9 more
wiley   +1 more source

Poly(ADP-Ribose) Polymerases [PDF]

The American Journal of Pathology, 2016
Neus Martínez-Bosch, Martin E. Fernández-Zapico, Pilar Navarro, José Yélamos   +3 more
openaire   +1 more source

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer. [PDF]

JCO Precis Oncol
Swisher EM, Konecny G, Cohen J, Colon-Otero G, Danziger N, Lin DI, Li G, Quintanilha JCF, Decker B, Ross JS, Gearing M, Baker K, Scott T, Poyser L, Vallejos P, Elvin JA, Graf RP.   +16 more
europepmc   +1 more source

Vitamin‐Responsive Disorders: From Molecular Basis to Clinical Presentation and Therapy

Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.
ABSTRACT Vitamin‐dependent cofactors are essential for numerous metabolic reactions, and defects affecting their uptake, conversion, utilisation, or regeneration constitute a heterogeneous group of inherited metabolic disorders (IMDs). Although dietary vitamin intake is sufficient to sustain coenzyme synthesis in healthy individuals, it is insufficient
Cécile Acquaviva, Yann Nadjar, Manuel Schiff, Christine Vianey‐Saban, Alain Fouilhoux, Jean‐François Benoist   +5 more
wiley   +1 more source

The first and second zinc finger domains from Poly-ADP-ribose polymerase 1 (PARP1) are modified by hydrogen sulfide. [PDF]

J Biol Inorg Chem
Williams AJ, Michel SLJ.
europepmc   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source